On Tuesday, September 22, Viking Therapeutics did something most biotech companies never manage: it answered the obesity drug industry’s hardest question. Its experimental drug VK2735 did not just help patients lose weight. It helped them keep the weight off with fewer injections. Shares surged as much as 38% in premarket trading and closed up roughly 36%, one of the stock’s biggest single-day gains since February 2024, on volume of about 15.7 million shares, more than five times the average, according to the Motley Fool.
The situation
Viking is a small San Diego biotech, worth about $4.8 billion after Tuesday’s move, trying to break into the weight-loss drug market owned by two giants. Eli Lilly holds about 61% of the U.S. GLP-1 market versus Novo Nordisk’s 39%, and Wall Street sees a roughly $100 billion market by 2030, per The Daily Upside’s September 23 edition. Viking has no product revenue. It ended June with $501.7 million in cash and short-term investments, down from $705.7 million at the end of 2025, and its second-quarter net loss widened to $128 million, or $1.10 per share, merlintrader reported. Six-month research and development spending reached $265.9 million. Viking is funding multiple obesity programs and manufacturing work at once, and its cash runway guidance runs to September 2027.
The industry’s dirty secret is adherence. GLP-1 drugs work beautifully in trials, but in the real world, persistence can fall as low as 27% after one year, per The Daily Upside. Weekly injections, side effects, and cost wear people down. A drug that works with monthly dosing changes the economics of the whole category.
What the study showed
Viking released top-line results from the VK2735 maintenance study on September 22. The design: 180 adults with a body mass index of at least 30 received weekly VK2735 for 21 weeks, then switched to less frequent maintenance dosing for 12 weeks, Zolmax reported. The numbers, from Viking’s own announcement and SEC filing:
- During the 21-week induction, patients on weekly dosing lost 16% to 19% of body weight, with no evidence of plateau, suggesting further loss with longer treatment.
- An exploratory weekly-dosing cohort reached 22% placebo-adjusted weight loss at week 33, with no plateau observed through 33 weeks.
- Patients who switched to every-other-week dosing preserved up to 97% of their week-21 weight loss, versus 61% for placebo.
- Monthly dosing preserved up to 90%, versus 61% for placebo.
- Gastrointestinal side-effect rates and discontinuations during maintenance were similar to placebo, an encouraging tolerability signal for longer treatment.
“We believe flexible dosing approaches will provide both patients and their providers with new options for improving long-term adherence to therapy and sustained weight management, both of which are essential to realizing the most critical benefits of weight loss, such as improved cardiovascular health, enhanced physical function, and increased quality of life,” CEO Brian Lian said, per the Motley Fool. Physician and former Obesity Society president Louis Aronne added that flexibility for patients and providers is paramount for treatment persistence. Oppenheimer raised its price target to $120 from $100.
Why it happened
The market had been waiting for exactly this readout. Viking’s two pivotal Phase 3 trials for injectable VK2735, VANQUISH-1 and VANQUISH-2, are fully enrolled with about 5,500 patients but have not reported. An oral Phase 3 program is expected to start in the fourth quarter of 2026. The maintenance data de-risks the franchise’s core commercial question: even if the drug works, will anyone stay on it? Every-other-week and monthly dosing with placebo-like tolerability is the industry’s best answer to that question so far.
The competition is not standing still. Zepbound did $13.5 billion in revenue last year versus Wegovy’s $12 billion, per The Daily Upside, and both Lilly and Novo are racing their own next-generation candidates through trials. For a patient, the difference Viking is selling is practical: twelve injections a year instead of fifty-two, fewer pharmacy trips, fewer weeks of nausea, and a dosing schedule that fits a normal life. That is the kind of advantage that shows up in insurance formulary decisions, which is where obesity drugs are actually won or lost.
The evidence, honestly weighed
A few caveats belong here. These are top-line results from an exploratory maintenance study of 180 patients, not a Phase 3 readout. Viking has guided its cash runway to September 2027 and has a $500 million at-the-market offering facility, so dilution risk is real if trials run long. There is also an outstanding Ligand dispute framing the risk side, per merlintrader. And the 52-week range, $24.78 to $43.15, shows how violently this stock reprices on data; Tuesday’s close near $41.65 sits at the top of that range.
Lessons
Three things this story teaches anyone watching biotech or their own health spending. First, in drug development, the question that moves the stock is rarely “does it work” but “will the real world use it,” and Viking aimed its study at exactly that. Second, small biotechs live on cash and catalysts: $501.7 million in the bank sounds comfortable until R&D runs at $265.9 million per half year. Third, the obesity market’s growth is no longer about who loses the most weight in 21 weeks; it is about who patients are still taking in year three. Viking just made a credible claim to that prize.
Published September 24, 2026. Sources: Viking Therapeutics via SEC 8-K, the Motley Fool, Quiver Quantitative, Stocktwits, Zolmax, merlintrader, The Daily Upside.
